Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAd3-EBO Z and MVA-EBO Z Prime-Boost in Senegal
NCT02485912Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Jul 2015
- Primary completion
- Jan 2016
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cAd3-EBOV and MVA-EBO Z in Ebola virus disease (EVD) (2 arms), sponsored by University of Oxford. Primary endpoint: Safety and Tolerability of Administration of ChAd3-EBO Z and MVA-EBO Z at 26 weeks. Started Jul 2015; status: completed.
02
Drugs
cAd3-EBOVMVA-EBO Z
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02485912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02485912.